Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Quimiocina para el tratamiento terapéutico del meduloblastoma

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOIT20180212002
Publicado:
07/03/2018
Caducidad:
08/03/2019
Resumen:
Un grupo de investigación italiano ha desarrollado un nuevo agente terapéutico para el tratamiento del meduloblastoma, uno de los tumores cerebrales pediátricos más extendidos. Este nuevo agente terapéutico es la quimiocina Cxcl3 (quimiocina C-X-C, ligando 3). El grupo de investigación busca socios con el fin de establecer acuerdos financieros y universidades y compañías farmacéuticas y biotecnológicas interesadas en alcanzar acuerdos de cooperación técnica para realizar los ensayos clínicos en humanos y desarrollar las formulaciones farmacéuticas.

Details

Tittle:
Chemokine for the therapeutic treatment of medulloblastoma
Summary:
An Italian research team has developed a novel therapeutic agent for treating medulloblastoma, one of the most widespread paediatric brain tumours.
The new therapeutic agent is the Cxcl3 chemokine (C-X-C motif, ligand 3).
The researchers are looking for partners interested in financial agreements and/or technical cooperation agreements.
Description:
An Italian research group has developed a novel therapeutic agent for treating medulloblastoma.
Medulloblastoma is one of the most widespread paediatric brain tumours, principally caused by the prolonged mitotic activity of glioma-propagating cells (GCPs) inside the external granular layer (EGL) of the cerebellum, making them potential targets of transforming insults, resulting in gene mutation and tumorigenesis.
The Italian researchers have recently shown that it is sufficient to delay the migration of the GCPs from the EGL, forcing them to proliferate for a longer period, to enhance the frequency of the transformation of the GCPs into a neoplastic cell.
The researches demonstrated this in a new mouse model, generated by crossing mice of a spontaneous medulloblastoma line (Patched1 heterozygous, which have hyperactivation of the Shh pathway) with the mouse lacking the medulloblastoma tumor-suppressor gene (Tis21); the resulting mice (Tis21-/-/Patched1+/-) show a dramatic increase of medulloblastoma frequency, with respect to the Patched1 heterozygous mice model. Remarkably, in Tis21-/-/Patched1+/- mice they observed not only increase of the frequency of medulloblastoma, but also an increase of the tumor lesions at the surface of cerebellum. This phenotype is surprisingly not associated to increase of proliferation of GCPs, but rather to a strong decrease of the migration of GCPs from the surface of cerebellum toward the internal layers of cerebellum.
In particular, they identified, by a genome-wide analysis, the chemokine Cxcl3 as a new responsible for the migration of GCPs. In neoplastic GCPs, Cxcl3 is reduced causing a huge increase of the frequency of medulloblastomas in consequence of the reduced migration of GCPs from the surface of cerebellum. Importantly, they have also shown that the treatment of cerebellar slices with Cxcl3 reduces the extension of diffused medulloblastoma lesions.
Therefore, ClCx3 is suggested as a novel therapeutic agent for treating medulloblastoma.

The Italian group is looking for new partners for Financial support to improve R-Y-D and cover the patent costs (i.e. business angels).
Furthermore the researchers are also interested in Technical cooperation agreement for sharing resources and skills; i.e. the researchers would like to cooperate with universities, pharmaceutical and biotech companies to proceed with the clinical studies on human and development of pharmaceutical formulations.
Advantages and Innovations:
The Italian group has performed in vivo tests on mice. The intracerebellar Cxcl3 administration with Alzet pumps for one month induced the disappearance of medulloblastoma in heterozygous Patched1 mice (which develop spontaneous medulloblastoma). The result confirms the inactivation mechanism of cancer cells through an induction of migration outside the proliferative zone, which forces them to differentiate and terminate the cancer program.
An additional series of experiments is currently being performed:
a) Expression of Cxcl3 receptor in various types of medulloblastoma (in humans);
b) Cxcl3 levels in cerebrospinal fluid.
Therefore, Cxcl3 could be inserted into a clinical trial in a man (not a child) with recurrences.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The partner sought is an investor, i.e. a business angel, interested in covering the patent costs and in supporting financially the research programme for favoring technological transfer (Financial agreement).
The researchers is also looking for other research institutes/universities and/or pharmaceutical and biotech companies to reach technical cooperation agreements for sharing resources and skills, proceed with the clinical studies on humans, and develop pharmaceutical solutions.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Italian

Keywords

Technology Keywords:
06 CIENCIAS BIOLÓGICAS
06001003 Citología, cancerología, oncología
06001002 Investigaciones clínicas, ensayos
06001 Medicina, salud humana
06001013 Tecnología médica / ingeniería biomédica